Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 183

The DOI matches its Crossref record.

A randomized controlled trial of licartin for preventing hepatoma recurrence after liver transplantation

Open access
Xu, Jing, Shen, Zhong-Yang, Chen, Xin-Guo, Zhang, Qing, Bian, Hui-Jie, Zhu, Ping, Xu, Hui-Yun, Song, Fei, Yang, Xiang-Min, Mi, Li, Zhao, Qing-Chuan, Tian, Rong, Feng, Qiang, Zhang, Si-He, Li, Yu, Jiang, Jian-Li, Li, Ling, Yu, Xiao-Ling, Zhang, Zheng, Chen, Zhi-Nan·2007·Hepatology

Abstract

Orthotopic liver transplantation (OLT) is the only curative therapy of HCC with underlying cirrhosis, but due to HCC metastasis and recurrence, its benefit is limited to a small population who meet the strict selection criteria. We previously reported that Licartin ([131I]mAb HAb18G/CD147) was safe and effective in treating HCC patients, and its antigen, HAb18G/CD147, was closely related to HCC invasion and metastasis. Here, we reported a randomized controlled trial to assess the post-OLT antirecurrence efficacy of Licartin in advanced HCC patients. We randomized 60 post-OLT patients with HCC, who were at tumor stage 3/4 and outside the Milan criteria before OLT, into 2 groups. Three weeks after OLT, the treatment group received 15.4 MBq/kg of Licartin, while the control group received placebo intravenously for 3 times with an interval of 28 days. At 1-year follow-up, the recurrence rate significantly decreased by 30.4% ( P = 0.0174) and the survival rate increased by 20.6% ( P = 0.0289) in the treatment group, compared with those in the control group. For the control group versus the treatment group, the hazard ratio for recurrence was 3.60 (95% confidence interval [CI], 1.50-8.60) and that for death was 3.87 (95% CI, 1.23–12.21). Licartin treatment also resulted in an earlier decreased AFP level and a longer time of normal AFP level than placebo ( P = 0.0016). No Licartin-related toxic effects were observed. Conclusion: Licartin is a promising drug for preventing post-OLT tumor recurrence in advanced HCC patients excluded by the currently strict criteria for OLT. HAb18G/CD147 can be a good drug target.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.21465

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 183

Metadata

Authors
Xu, J., Shen, Z.-Y., Chen, X.-G., Zhang, Q., Bian, H.-J., Zhu, P., Xu, H.-Y., Song, F., Yang, X.-M., Mi, L., Zhao, Q.-C., Tian, R., Feng, Q., Zhang, S.-H., Li, Y., Jiang, J.-L., Li, L., Yu, X.-L., Zhang, Z., & Chen, Z.-N.
Venue
Hepatology
Published
2007-02
Volume
45
Issue
2
Pages
269-276
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2027549866
Cited by
183
References
0
FWCI
4.86
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized controlled trial of licartin for preventing hepatoma recurrence after liver transplantation. https://app.cochat.ai/papers/10.1002/hep.21465
The paper
Xu, J., Shen, Z.-Y., Chen, X.-G., Zhang, Q., Bian, H.-J., Zhu, P., Xu, H.-Y., Song, F., Yang, X.-M., Mi, L., Zhao, Q.-C., Tian, R., Feng, Q., Zhang, S.-H., Li, Y., Jiang, J.-L., Li, L., Yu, X.-L., Zhang, Z., & Chen, Z.-N. (2007). A randomized controlled trial of licartin for preventing hepatoma recurrence after liver transplantation. Hepatology. https://doi.org/10.1002/hep.21465

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.